GARCHING, Germany–(BUSINESS WIRE)–#NETcancer–ITM Isotopen Technologien München AG (ITM), a radiopharmaceutical group
of companies, announced today the appointment of Michael Lee-Chin to its
supervisory board, starting May 23, 2019. Mr. Lee-Chin is founder and
chairman of Portland Holdings, a privately held investment company
headquartered in Burlington, Ontario, Canada. Portland Holdings is
committed to investing in businesses active in strong, long-term growth
industries that also seek to improve the social well-being of the
communities in which they operate.
The philosophy of Michael Lee-Chin and Portland Holdings is to “do well
and do good” – building strong businesses that are giving back to
society. Over the years, Portland has contributed significant capital
and human resources to a variety of initiatives in education, culture,
health care and humanitarian assistance. For his entrepreneurial and
philanthropic work, Mr. Lee-Chin has received numerous awards and
honors, including degrees from several distinguished universities. In
2008, he was awarded one of Jamaica’s highest honors, the Order of
Jamaica for his significant contributions in business and philanthropy.
In February 2018, he was appointed to the Order of Ontario, the Canadian
province’s highest honor, reserved for those whose contributions have
shaped the province, the country and beyond.
“We are extremely delighted that Michael joined our supervisory
board. His exceptional business acumen and his entrepreneurial spirit
will further support our strong growth and our goal to improve the
wellbeing and quality of life of cancer patients worldwide by bringing a
new generation of targeted radiopharmaceuticals to the market,” said
Udo J. Vetter, Chairman of the ITM Supervisory Board.
“I really look forward to helping ITM’s exceptional team shaping the
future of Targeted Radionuclide Therapy and effective cancer treatments
in general. ITM’s dedication, innovative pipeline and passion for the
well-being of those in need align perfectly with the values I strive to
achieve with my other business ventures,” commented Michael
Lee-Chin. “Targeted Radionuclide Therapy has the potential to
revolutionize cancer therapy. I am grateful; I now have the opportunity
to play my part in making this type of treatment available to even more
patients worldwide.”
– Ends –
Contacts
Nicola Scharrer
Head of Marketing
Phone: +49 89 3298986-151
Email:
[email protected]
Media
Contact: WE Communications
Sebastian Klein
Account Manager
Phone:
+49 89 628175-46
Email: [email protected]
